Masitinib mesylate

N/A

Report date: 2026/05/07 20:00:36
NME

Base Information

Drug NameMasitinib mesylate
Drug Alias NameMasitinibum马赛替尼甲磺酸盐Masitinib mesilate玛司替尼甲磺酸盐马赛替尼 +[14] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPlatelet-derived growth factor receptor inhibitorsFibroblast growth factor receptor 3 antagonistsStem cell growth factor receptor inhibitors +[4] 
TargetsStem cell growth factor receptorPlatelet-derived growth factor receptorFibroblast growth factor receptor 3 +[4] 
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)PsoriasisAmyotrophic Lateral Sclerosis +[17] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBulgaria +[37] 
CombinationsNo
Global Highest StatusNDA/BLA
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesAb Science
China Registration ClassN/A

Develop Information

Active CompaniesExcella GmbhAb ScienceBoji Medical Technology Co Ltd
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)Amyotrophic Lateral SclerosisAlzheimer Disease +[7] 
Inactive IndicationsPsoriasisMultiple Sclerosis, Chronic ProgressiveMultiple Sclerosis +[10] 

Other Information

ATC CodeL01EX06
Related LinksWikipediaKEGG